October 1, 2026
This week: Waning gene therapy data, a biotech IP lawsuit, shifting GLP-1 messaging, and a deep dive into the erosion of trust in science.
September 24, 2026
This week: Heidi Overton's nomination to lead a turbulent FDA and a deep dive into the competitive rise of China's booming biotech industry.
September 17, 2026
Psychedelics go mainstream with new data and Big Pharma deals, while restrictive immigration policies threaten the future of US science.
September 10, 2026
Major heart drug trial failures shake faith in genetic validation, chilling investment in cardiovascular R&D. What does this mean for patients?
July 30, 2026
A fugitive in the C-suite, Capricor's data clash with the FDA, and a look at biotech's regulatory and personnel shakeups.
July 23, 2026
A father's quest for a rare disease cure, telehealth GLP-1 prescribing risks, and a Novo vs. Lilly lawsuit.
July 16, 2026
Kalshi's new biotech prediction markets spark debate. A bioethicist weighs the promise of better data against the ethical risks to clinical trials.
July 9, 2026
STAT's Bob Herman & whistleblower Chris Deacon expose the employer health insurance crisis. Plus, Vertex's $10B deal & Anthropic's drug dev plans.
June 18, 2026
New hope for Huntington's as the FDA reverses course on a gene therapy, plus a one-year report card on RFK Jr.'s progress as HHS secretary.
June 11, 2026
This week: A reality check on the obesity drug pipeline from ADA, a record biotech IPO, and a deep-dive into the controversial peptide BPC-157.
June 4, 2026
A patient's powerful story on RevMed's new pancreatic cancer drug, plus market turmoil and key data reveals from the ASCO conference.
May 28, 2026
Biotech exec Jeremy Levin warns the industry is at a turning point: science thrives, but the system is fracturing under political pressure.
May 21, 2026
Biotech debates IP protection from China, partnerships, and big bets in longevity, featuring an interview with Retro Biosciences' CEO.
May 14, 2026
FDA in flux as Commissioner Makary resigns. Sen. Cassidy's political future is uncertain. Plus, updates on Biogen's Alzheimer's drug & REGENXBIO.
May 7, 2026
Seaport's IPO adventure, Novo vs. Lilly in the obesity pill race, and mounting pressure on FDA Commissioner Makary headline this 400th episode.
April 30, 2026
This week: Viridermix unveils hair-raising trial data for its oral drug, and Servier's CEO discusses its $2.5B Day One Biopharma deal.
April 23, 2026
Lilly's $3.25B bet on Colonia's in-vivo CAR-T, a Medicare obesity drug plan unravels, and pharma's use of telehealth to drive scripts.
April 16, 2026
Biotech breakthroughs: A new drug nearly doubles pancreatic cancer survival, while an off-the-shelf CAR-T therapy shows promise in preventing lymphoma relapse.
April 2, 2026
Biotech battles: A price war in obesity drugs, a surge in Q1 M&A, and an investor plea to Trump's FDA over rare disease drug flexibility.
March 26, 2026
Lilly's M&A struggles, Merck's $7B Terns buy, Wave's weight loss drug falters, and Allogene's novel off-the-shelf CAR-T approach.
March 20, 2026
Biotech news on obesity drugs and Lilly's risks, plus an interview with Stelios Papadopoulos on the FDA's woes, China's rise, and innovation.
March 12, 2026
Prasad exits the FDA, Novo settles with Hims, and a deep dive into biotech VC Boris Nikolic's comeback despite his deep ties to Jeffrey Epstein.
March 5, 2026
This week: The FDA's tough stance on sham surgeries for gene therapy trials, and Spire Therapeutics aims to breach the IBD efficacy ceiling.
February 26, 2026
Biotech update: M&A is simmering, the FDA's rare disease stance is creating turmoil, and Lilly's lead over Novo in the obesity market widens.
February 19, 2026
FDA reverses on Moderna's flu shot, Compass's psychedelic drug shows promise, and Hims faces lawsuits over its compounded weight-loss pill.
February 12, 2026
The FDA's unusual refusal to review Moderna's mRNA flu vaccine sparks controversy over regulatory unpredictability and political influence.
February 5, 2026
GLP-1 wars heat up with divergent Lilly/Novo outlooks, Casgevy's rollout stalls on cell collection, & a psychedelic drug hits a WH roadblock.
February 3, 2026
Lipitor's journey from blockbuster cholesterol drug to medical controversy, questioning the true benefit versus risk for millions.
January 29, 2026
Huntington's advocate Lauren Holder details the community's fight for Unicure's gene therapy after a shocking FDA setback on its approval path.
January 22, 2026
A measles outbreak threatens the U.S.'s elimination status, while hospitals brace for Medicaid cuts and navigate a complex political landscape.
January 14, 2026
At JPM, Novo CEO talks obesity market strategy & DTC. VC Bob Nelsen covers biotech's future, China competition, and the impact of AI.
January 8, 2026
Big Pharma enters JPM week with a bullish outlook after navigating political threats, fueling M&A expectations amid cautious investor sentiment.
December 18, 2025
Biotech's 2025 review: The market is back, driven by M&A and fading macro risks. Experts discuss GLP-1 pricing, CEO awards, and a 2026 IPO surge.
December 11, 2025
ASH conference highlights, new obesity drug data, and a deep dive into the precarious future of American science under a new political landscape.
